Healthcare Triangle Amends 8-K on Material Agreements, Equity Sales

TL;DR

**Healthcare Triangle filed an 8-K/A about new agreements and equity sales, but it's light on details.**

AI Summary

Healthcare Triangle, Inc. filed an 8-K/A on January 12, 2024, amending a previous report from December 28, 2023. This amendment clarifies details regarding an "Entry into a Material Definitive Agreement," "Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement," and "Unregistered Sales of Equity Securities." While the filing indicates these events occurred, it does not provide specific dollar amounts or share counts, making it difficult for investors to assess the precise impact of these material agreements and equity sales on the company's financial health or their ownership stake.

Why It Matters

This filing signals significant corporate actions, including new financial obligations and equity sales, which could dilute existing shareholders or impact the company's debt levels. Without specific details, investors lack crucial information to evaluate the potential positive or negative effects on the stock price.

Risk Assessment

Risk Level: medium — The lack of specific financial details regarding material agreements and equity sales creates uncertainty for investors, making it a medium risk.

Analyst Insight

Investors should monitor future filings for specific details on the material agreements and equity sales mentioned, as the current filing lacks the necessary information to assess financial impact or dilution.

Key Players & Entities

• Healthcare Triangle, Inc. (company) — the registrant filing the 8-K/A
• 001-40903 (other) — Commission File Number for Healthcare Triangle, Inc.
• 84-3559776 (other) — IRS Employer Identification No. for Healthcare Triangle, Inc.
• December 28, 2023 (date) — date of the earliest event reported in the original 8-K
• January 12, 2024 (date) — date of the 8-K/A filing

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share HCTI The Nasdaq Stock Mar
• $5,200,000 — the aggregate principal amount of up to $5,200,000 which will result in gross proceeds to
• $4,420,000 — s to the Company in the amount of up to $4,420,000 due to the original issue discount, and
• $2,000,000 — the Investor in the principal amount of $2,000,000 which resulted in gross proceeds to the
• $1,700,000 — ted in gross proceeds to the Company of $1,700,000 and Warrants to purchase up to an aggre
• $3.44688 — fixed conversion and exercise price of $3.44688 per share, respectively, subject to adj
• $1,000,000 — or in the aggregate principal amount of $1,000,000, for gross proceeds to the Company of $
• $850,000 — 0, for gross proceeds to the Company of $850,000. Such additional principal amounts, if
• $2,200,000 — or in the aggregate principal amount of $2,200,000, for gross proceeds to the Company of $
• $1,870,000 — 0, for gross proceeds to the Company of $1,870,000. Such additional principal amounts, if
• $3 — at an initial conversion price equal to $3.44688, provided that if an event of def

Filing Documents

• ea191572-8ka1_health.htm (8-K/A) — 55KB
• ea191572ex4-1_health.htm (EX-4.1) — 210KB
• 0001213900-24-003375.txt ( ) — 496KB
• hcti-20231228.xsd (EX-101.SCH) — 3KB
• hcti-20231228_lab.xml (EX-101.LAB) — 33KB
• hcti-20231228_pre.xml (EX-101.PRE) — 22KB
• ea191572-8ka1_health_htm.xml (XML) — 4KB

03

Item 2.03. Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 2.03 in its entirety. Item 3.02. Unregistered Sales of Equity Securities. The information set forth in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 3.02 in its entirety. Item 9.01 Financial Statements and Exhibits. (d) Exhibits 4.1 Form of Senior Secured 15% Original Issue Discount Convertible Promissory Note.* 4.2 Form of Common Stock Purchase Warrant.* (incorporated by reference to Exhibit 4.2 to Company's 8-K filed with the Commission on January 2, 2024) 10.1 Securities Purchase Agreement.* (incorporated by reference to Exhibit 10.1 to Company's 8-K filed with the Commission on January 2, 2024) 10.2 Security Agreement.* (incorporated by reference to Exhibit 10.2 to Company's 8-K filed with the Commission on January 2, 2024) 10.3 Pledge Agreement.* (incorporated by reference to Exhibit 10.3 to Company's 8-K filed with the Commission on January 2, 2024) 10.4 Subsidiary Guarantee* (incorporated by reference to Exhibit 10.4 to Company's 8-K filed with the Commission on January 2, 2024) 10.5 Intercreditor Agreement* (incorporated by reference to Exhibit 10.5 to Company's 8-K filed with the Commission on January 2, 2024) 10.6 Form of Registration Rights Agreement.* (incorporated by reference to Exhibit 10.6 to Company's 8-K filed with the Commission on January 2, 2024) 99.1 Press Release, dated January 2, 2024 (incorporated by reference to Exhibit 99.1 to Company's 8-K filed with the Commission on January 2, 2024) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Certain information in these exhibits has been omitted because it is both not material and the type of information that the registrant trea

View Full Filing

View this 8-K/A filing on SEC EDGAR